Gui Liu1, Lauri E Markowitz1, Susan Hariri1, Gitika Panicker2, Elizabeth R Unger2. 1. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. 2. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4 HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-risk (HR) types (31/33/45/52/58). Measuring seropositivity before vaccine introduction provides baseline data on exposure to types targeted by vaccines. METHODS: We determined seroprevalence of HPV 6/11/16/18/31/33/45/52/58 among 4943 persons aged 14-59 years who participated in the National Health and Nutrition Examination Survey, 2005-2006. RESULTS: Among females, seroprevalence was 40.5% for any of the 9 vaccine types, 30.0% for any 7 HR types (16/18/31/33/45/52/58), 19.0% for any 5 additional types (31/33/45/52/58), and 18.3% for 16/18. Compared with non-Hispanic whites, non-Hispanic blacks had higher seroprevalence of 31/33/45/52/58 (36.8% vs 15.9%) and 16/18 (30.1% vs 17.8%), while Mexican Americans had higher seroprevalence of 31/33/45/52/58 (23.6% vs 15.9%) (P < .05 for all). In multivariable analyses of data from females, race/ethnicity, number of sex partners, and age were associated with 16/18 and 31/33/45/52/58 seropositivity. Seropositivity was lower among males than among females (P < .001 for all type categories). CONCLUSIONS: In 2005-2006, about 40% of females and 20% of males had serological evidence of exposure to ≥1 of 9 HPV types. Seroprevalence of all type categories, especially HPV 31/33/45/52/58 among females, varied by race/ethnicity. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4 HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-risk (HR) types (31/33/45/52/58). Measuring seropositivity before vaccine introduction provides baseline data on exposure to types targeted by vaccines. METHODS: We determined seroprevalence of HPV 6/11/16/18/31/33/45/52/58 among 4943 persons aged 14-59 years who participated in the National Health and Nutrition Examination Survey, 2005-2006. RESULTS: Among females, seroprevalence was 40.5% for any of the 9 vaccine types, 30.0% for any 7 HR types (16/18/31/33/45/52/58), 19.0% for any 5 additional types (31/33/45/52/58), and 18.3% for 16/18. Compared with non-Hispanic whites, non-Hispanic blacks had higher seroprevalence of 31/33/45/52/58 (36.8% vs 15.9%) and 16/18 (30.1% vs 17.8%), while Mexican Americans had higher seroprevalence of 31/33/45/52/58 (23.6% vs 15.9%) (P < .05 for all). In multivariable analyses of data from females, race/ethnicity, number of sex partners, and age were associated with 16/18 and 31/33/45/52/58 seropositivity. Seropositivity was lower among males than among females (P < .001 for all type categories). CONCLUSIONS: In 2005-2006, about 40% of females and 20% of males had serological evidence of exposure to ≥1 of 9 HPV types. Seroprevalence of all type categories, especially HPV 31/33/45/52/58 among females, varied by race/ethnicity. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
human papillomavirus; racial differences; seroprevalence
Authors: Mina Yeom; In-Hyeok Kim; Jae-Kwon Kim; KyeongJin Kang; Robert L Eoff; F Peter Guengerich; Jeong-Yun Choi Journal: Chem Res Toxicol Date: 2016-03-04 Impact factor: 3.739
Authors: Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins Journal: Genes Dev Date: 2018-06-26 Impact factor: 11.361
Authors: Shams Rahman; Christine M Pierce Campbell; Tim Waterboer; Dana E Rollison; Donna J Ingles; B Nelson Torres; Angelika Michel; Staci L Sudenga; Michael Pawlita; Luisa L Villa; Eduardo Lazcano Ponce; Amy R Borenstein; Wei Wang; Anna R Giuliano Journal: J Gen Virol Date: 2016-10-06 Impact factor: 3.891
Authors: Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer Journal: Sex Transm Dis Date: 2016-03 Impact factor: 2.830
Authors: Katherine K S Rieth; Steven R Gill; Abberly A Lott-Limbach; Mark A Merkley; Nathalia Botero; Paul D Allen; Matthew C Miller Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-03-01 Impact factor: 6.223